Dora Vallejo-Ardila: A Global Shift from Promise to Practice in Precision Oncology
Dora Vallejo-Ardila, Senior Medical Monitor/Clinical Research Physician at Avance Clinical, shared a post on LinkedIn:
“Precision Oncology: A Global Shift from Promise to Practice
Precision oncology isn’t just about the technology. It’s about access, implementation, and outcomes.
In Australia, the move toward free access to comprehensive genomic profiling (CGP) through publicly funded programs like PrOSPeCT and ZERO is reshaping what equitable, data-driven care looks like. These initiatives are allowing thousands of Australians with advanced or incurable cancers to access targeted therapies and clinical trials—not just based on their diagnosis, but on their individual cancer’s biology.
Compare this to the U.S., where access to CGP is largely insurance-dependent, and while leading-edge in terms of biotech innovation, remains fragmented in delivery and affordability.
The business case? Strong:
- In Australia, government-supported CGP is showing promise in increasing access and equity, reducing treatment mismatch, and potentially lowering long-term costs.
- In the U.S., payer-funded models show a modest cost (~$0.01 PMPM), yet add measurable life-years for patients with NSCLC.
Meanwhile, global pharma leaders like Roche and AstraZeneca are investing in pipelines rich with targeted therapies—from ALK inhibitors to ADCs and bispecifics. But the key question remains:
Will these treatments reach the right patients, at the right time, in a cost-effective way?
As we see more public-private partnerships and real-world data emerging from platforms like ASPiRATION in Australia and CGP cost-effectiveness models in the U.S., it’s clear that pairing innovative science with public health infrastructure will define the next frontier of cancer care.
A closer look at the latest analysis published by Frank Lin et al.”
Title: Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.
Journal: JCO
Author: Scott Spencer, Weicheng Ye, Christine Napier, Frank Po-Yen Lin, David Morgan Thomas, Ronald Chan, Mandy L Ballinger, Rachael L Morton, Slavica Berber, Denise Zou, Siyang Peng
More posts featuring Dora Vallejo-Ardila on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023